While VEGF receptor (VEGFR)-targeted therapies are important in the management of several cancer types, many patients exhibit no or limited respond to treatment, due in part to tumor cell resistance through alternative molecular pathways [4]. The gene discussed is KDR; the disease is neoplasm.